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Available online 27 March 2014To study the possible involvement of potential environmental pathogens in the pathogenesis of
autoimmune diseases, it is essential to investigate antibody responses to a variety of environmental
agents and autologous components. However, none of the conventional ELISA buffers can prevent
the false positive and negative reactions attributed to its principal, which utilizes the high binding
affinity of proteins to plastic surfaces. The aims of this study are to reveal all types of non-specific
reactions associated with conventional buffer systems, and to re-investigate antibody responses to
potential environmental pathogenic and autologous antigens in patients with autoimmune
diseases using a newly developed buffer system “ChonBlock™” by ELISA.
Compared to conventional buffers, the new buffer was highly effective in reducing the most
intense false positive reaction caused by hydrophobic binding of immunoglobulin in sample
specimens to plastic surfaces, “background (BG) noise reaction”, and other non-specific reactions
without interfering with antigen–antibody reactions. Applying this buffer, we found that IgG
antibody responses to Escherichia coliO111:B4, E. coli lipopolysaccharide (LPS) and peptidoglycan
polysaccharide (PG-PS) were significantly lower or tended to be lower in patients with
rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), whereas IgA antibody
responses to these antigens were equal or tended to be higher compared to normal controls. As a
consequence, the IgA/IgG antibody ratios against these agents were significantly higher in
patients with RA and SLE, except for Crohn's disease, which showed significantly higher IgG
responses to these antigens.
To assay antibodies in human sera, it is indispensable to eliminate false positive and negative
reactions by using an appropriate buffer system, and to include antigen non-coated blankwells to
determine BG noise reactions of invidual samples. Finally, based on our preliminary analysis in
this study, we propose that low IgG antibody responses to potential pathogenic environmental
factors may be the fundamental disorder in autoimmune diseases.
© 2014 Chondrex, Inc. Published by Elsevier B.V. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/3.0/).Keywords:
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hionoya).
.V. This is an open access article1. Introduction
A variety of immunoassay systems, such as ELISA, are
widely used for assaying antibodies and antigens at high
sensitivity using micro-titer plates or small bead particles as a
carrier of targetmolecules. Unfortunately, this systemhas been
used without fully comprehending the numerous vexingunder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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binding affinity of proteins to plastic surfaces as we reported
previously (Fujii et al., 1989).
Indeed, none of the conventional ELISA buffer systems
currently used can be applied for assaying antibodies in human
sera due to the poor blocking effect on non-specific reactions,
especially the most intense false positive reaction caused by
hydrophobic binding of immunoglobulin components in
sample specimens to plastic surfaces or ‘BG noise reaction’.
Although the unique BG noise reaction of individual samples
can be determined by including control wells not coated with
antigen, these control wells were and still are frequently
omitted in plates made by investigators conducting basic
research, and are not even included in commercially prepared
plates meant for automated analysis. Consequently, data
influenced largely by a variety of false positive reactions have
led to numerous uncertain conclusions and misunderstand-
ings. In some instances, OD values of control wells can be as
high as the values in antigen-coated wells regardless of the
antigen (Fujii et al., 1989; de Vries et al., 1992), and more
importantly, BG noise values in autoimmune disease groups
are higher than those in normal controls (Fujii et al., 1989).
To solve this fundamental problem in ELISA, we previously
developed an improved antibody assay system using a buffered
heterologous serum (rabbit and goat) as a blocking and sample
dilution buffer (Fujii et al., 1989) and applied it to analyze
anti-collagen antibodies in RA (Terato et al., 1990, 1996).
Unfortunately, this protocol cannot be applied to assay
antibodies against environmental agents, since heterologous
serum contain antibodies, which share similar antigen specific-
ity and competitively inhibit relevant antibodies in test samples.
Therefore, it is absolutely imperative to have an appro-
priate assay system, which eliminates these false positive and
negative reactions involved in ELISA for any field of study. In
this study, we initially re-investigated the individual types of
non-specific reactions in conventional ELISA systems, and
then evaluated the blocking efficacy of a newly developed
ELISA buffer, ChonBlock™ (Chondrex Inc., Redmond, WA),
from every possible angle.
Lastly, we applied the new buffer system to assay antibody
levels against a variety of environmental agents in human sera
to study the possible involvement of potential environmental
pathogens in the pathogenesis of autoimmune diseases. In this
preliminary study, we found that IgG antibody responses to
potential pathogenic antigens, such as Escherichia coli, lipopoly-
saccharide (LPS) from E. coli, and also peptidoglycan polysac-
charide (PG-PS) from Streptococcus pyogenes, are significantly
lower or tended to be lower. As a consequence, the IgA/IgG
antibody ratios against these antigens are significantly higher in
patients with RA and SLE compared to normal controls. In
contrast, significantly high IgG antibody responses to these
pathogens and LPS produced by Porphyromonas gingivalis
(Pg-LPS) were observed in patients with Crohn's disease.
2. Materials & methods
2.1. Human serum samples
The human serum samples used for this study were from
15 normal controls, 61 patients with RA, 7 patients with SLE
and 7 patients with Crohn's disease. Among these, sera from10 healthy controls, 7 patients with SLE and Crohn's disease
were obtained from Bioreclamation LLC, NY, whereas the
remaining sera were selected from our frozen stock. An
institutional Review Board (IRB) exemption was granted from
theWestern Institutional Review Board (WIRB), Olympia, WA,
USA. According to the WIRB Regulatory Affairs Department,
this research project met the conditions for exemption under
45 CFR 46.101(b)(4).
2.2. Microtiter plates
Two types of ELISA plates were used for these studies: a high
affinity Immulon 2 HB plate (Thermo Fisher, Waltham, MA) for
coating protein antigens and E. coli by hydrophobic binding, and
Costar DNA binding plate (Corning Inc, Corning, NY) for
coupling CCP and a control peptide by covalent binding.
2.3. ELISA buffers and reagents
Seven different buffers were used to compare their blocking
effects on the hydrophobic binding of human serum immuno-
globulin components to plastic surfaces: 1) 0.1 M Tris-Saline
Buffer, pH 7.8, containing 0.05% Tween 20 (TSB-Tween), 2) 1%
BSA in TSB-Tween (BSA-Tween), 3) 2% milk casein enzyme
hydrolysate in TSB-Tween (Milk-Tween), 4) radioimmunoassay
buffer (RIA) containing 1% BSA, 350 mMNaCl, 1% Triton-X-100,
0.5% Na-deoxycholate and 0.1% sodium dodecyl sulfate (SDS) in
0.01 M Tris–HCl buffer, pH 7.6, 5) RIA supplemented with 10%
normal goat serum (RIA-10% NGS), 6) undiluted buffered
normal goat serum with TSB (100% NGS) and 7) ChonBlock™,
a protein-based blocking/sample dilution buffer, not containing
any biologically or immunologically active components. In
addition, Triton X buffer provided in a commercially available
CCP antibody assay kit (BioRad, Hercules, CA) was used for an
inhibition test of anti-CCP antibodies.
HRP-conjugated goat anti-human IgG (Fc-specific: Cat #
2047-5) (Southern Biotech, Birmingham, AL) and anti-human
IgA antibodies (alpha-specific: Cat # 14-10-01) (KPL, Gaithers-
burg, MD) were used for detecting human serum IgG and IgA,
respectively. These detection antibodieswere diluted at 1/12,000
and 1/1500, respectively, by ChonBlock™ detection antibody
dilution buffer otherwise indicated.
2.4. Synthesis of peptide antigens
Two cyclic peptides, a cyclic citrullinated peptide (CCP)(cfc1-
cyc: HQCHQESTXGRSRGRCGRSGS, circled between two Cs, X:
Citrulline) corresponding with filaggrin (306–324), a filament
associated protein, and a negative control cyclic peptide
(cf0-cyc: HQCHQESTRGRSRGRCGRSGS, circled between two
Cs), were synthesized at Biosynthesis (Lewisville, Texas)
according to the method described by Schellekens et al.
(Schellekens et al., 2000) and Perez et al. (Pérez et al., 2006).
2.5. Coating microtiter plates with antigen
Protein antigens were dissolved in PBS, pH 7.4, at 5 μg/ml,
and added to Immulon 2 HB plate at 100 μl/well. The plates
were incubated overnight at 4 °C. An E. coli (heat killed)
suspension (OD600: 10) supplied by Asama Chemicals (Tokyo,
Japan) was diluted 1/100 with distilled water, and added to
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room temperature.
Synthetic peptides and IgG free BSA (Jackson Immuno-
Research, West Grove, PA) were dissolved at 10 μg/ml in
0.05 M NaHCO3, and added to Costar DNA Binding Plates at
100 μl/well. The plates were incubated overnight at 4 °C to
allow covalent binding of the peptide to the plastic surfaces. To
measure anti-CCP antibodies using the RIA-10% NGS buffer
system, the control wells were coupled with glycine instead of
IgG-free BSA used by Schellekens et al. (Schellekens et al.,
2000) and Perez et al. (Pérez et al., 2006), because human sera
contain antibodies that bind stronglywith BSA (Andersen et al.,
2004) as described later. All antigen treated plates were
washed six times with cold LPS-free filtered water, dried at
room temperature and stored at 4 °C until use.
2.6. Inhibition test
Inhibition of anti-CCP antibodies: Serum from RA #3
was diluted at 1/800 in RIA-10% NGS, Triton X buffer and
ChonBlock™, respectively, and 0.8 ml of this solution was
mixedwith 0.2 ml of CCP- and control-peptide (0.1–1.0 mg/ml
in distilled water) solutions, respectively. After overnight
incubation at 4 °C, the samples were assayed in non-antigen
and CCP-coupled wells.
Inhibition of anti-E. coli antibodies: An E. coli suspension
in distilled water (OD650 value: 10) was dispended into
micro-centrifuge tubes by 100, 50, 25, 12.5, 6.25 and 3.125 μl,
and spun at 10,000 rpm for 5 min. A human serum sample
(NL #2) was diluted at 1/100 with 1% BSA-Tween, 100% NGS
and ChonBlock™, respectively, and 100 μl of individual solution
was added to E. coli pellets, and incubated overnight at 4 °C. The
supernatant was further diluted to 1/2500 with corresponding
buffer, and assayed in antigen non-coated and E. coli-coated
Immulon 2HB plates.
2.7. Standards for human serum antibody assays
Standards for assaying antibodies against individual antigens
were prepared from selected human sera. The highest dose of
standard was adjusted to give 3.0 ± 0.1 of OD 450 value, and
defined as 32 units/ml. For example, for IgG antibody assays, a
normal serum, NL # 2, was diluted as follows depending on
antigens, E. coli: 1/2500, LPS: 1/300, PG-PS: 1/5000, Pg-LPS:
1/800, ovalbumin (OVA): 1/2000, BSA: 1/1500 and bovine IgG:
1/4000. In addition, for IgG anti-CCP antibody assay, a combined
serum from 25 anti-CCP-antibody positive patients with RAwas
diluted at 1/500. For IgA antibody assays, sera from 3 normal
individuals absorbed by protein G as described later were
diluted depending on antigens, LPS: NL #5 diluted at 1/250,
E. coli: NL #8 diluted at 1/2000, and PG-PS: NL #8 diluted
1/4000. Since serum IgA anti-Pg-LPS antibody levels were
generally low, NL #8 diluted at 1/500 was used as 8 units/ml.
2.8. ELISA procedure for human serum antibody assay
For IgG antibody assays, human serum samples were
diluted with ChonBlock™ sample dilution buffer depending
on antigens: E. coli (1/10,000), LPS (1/1000), PG-PS (1/
20,000), Pg-LPS (1/1000), OVA (1/5000), BSA (1/500),
bovine IgG (1/20,000), and CCP (1/500). For IgA antibodyassays, all serum specimens including standards were
absorbed with Protein G to remove IgG as follows. Serum
was diluted at 1/100 with ChonBlock™ sample dilution
buffer, and 100 μl of the diluted serum was then mixed with
100 μl of Protein G suspension (30%) in PBS, incubated
10 min at room temperature, and spun at 10,000 rpm for
3 min with a table top centrifuge. The supernatants were
further diluted with ChonBlock™ sample dilution buffer
depending on antigens: E. coli (1/4000), LPS (1/1000), PG-PS
(1/10,000) and Pg-LPS (1/1000).
Plates were blocked at room temperature for 1 h with
ChonBlock™ sample dilution buffer just before use, andwashed
with PBS-Tween. Then, 100 μl of diluted test sampleswas added
into antigen non-coated control wells and antigen-coatedwells,
and incubated at room temperature for 2 h. After washing the
plate with PBS-Tween, 100 μl of HRP-conjugated detection
antibody diluted by ChonBlock™ detection antibody dilution
buffer was added into all wells, and reacted at room tempera-
ture for 2 h. Color was developed at room temperature for
25 min by adding 100 μl of TMB solution (Cat # 34028, Thermo
Scientific, Rockford, Illinois), and stopped by 50 μl of 2N sulfuric
acid. The absorbance valuesweremeasured at 450/630 nm. The
samples, which gave higher OD values than the highest
standard (32 units/ml), were re-assayed at higher dilution.
The results were shown as kilo-units/ml (units/ml).
2.9. Statistic analysis
Data is expressed as the mean ± standard deviation. For
statistical evaluation, the unpaired Student's t-test was used to
determine the significance of differences between normal
control and disease groups. Results were shown using p-values
with 5% level of significance if not otherwise stated.
3. Results
3.1. Intense false positive reaction caused by hydrophobic binding
of human serum immunoglobulin components to plastic surfaces
In an ELISA, four types of false positive reactions can be
encountered regardless of the antigens coated on the ELISA
plate: 1) non-specific reaction caused by the secondary
antibody, 2) hydrophobic binding of immunoglobulin com-
ponents in sample specimens to plastic surfaces, 3) ionic
interaction between immunoglobulin in sample specimens
and antigen, and 4) immune-recognition of blocking agents
by antibodies in serum specimens (e.g. human anti-BSA and
anti-bovine IgG antibodies). In addition, two false negative
reactions are considered: 1) the competitive inhibition of test
antibodies by relevant antibodies present in animal serum,
such as NGS, which is added to the sample dilution buffer,
and 2) denaturation of enzymes conjugated to detection
antibodies, antigens and antibodies by SDS contained in RIA
and RIA-10% NGS buffer.
Among these, the hydrophobic binding of immunoglob-
ulin in sample specimens to plastic surfaces causes the most
intense false positive reaction in an ELISA. Therefore, we first
compared the blocking efficacy of commonly used buffers
and ChonBlock™ against this non-specific reaction. For
this study, serum from a patient with RA (RA#13) was
serially diluted with seven different buffers, and reacted with
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commonly used buffers (TSB, RIA, RIA-10% NGS, 1% BSA-Tween,
and 2% milk casein) was effective in reducing the binding of
human immunoglobulin to the Immulon 2 HB plate. Compared
to these buffers, 100% NGS and ChonBlock™ effectively
prevented the binding of human immunoglobulin to plastic
surfaces, and notably ChonBlock™was 2–3 time more effective
than 100% NGS (Fig. 1a). Similar results were observed in a
Costar Covalent plate (Fig. 1b). Interestingly, RIA-10% NGS
was more effective in the Costar plate than the Immulon 2 HD
plate.
To confirm these results, 10 sera from normal controls
and 10 sera form patients with RA were diluted at 1/200
with different buffers, and added to unblocked antigen
non-coated plain wells of Immulon 2 HB plates to accentuate
the non-specific reactions. As shown in Fig. 2a, both normal
and RA sera diluted with 1% BSA-Tween and RIA-10% NGS
gave significantly high BG noise values compared to samples
diluted by 100% NGS and ChonBlock™. Importantly, the BG
noise values of RA sera were significantly higher than those
of normal controls (p b 0.05) in 1% BSA-Tween as reported
(Fujii et al., 1989). On the other hand, the BG noise values of
RA sera diluted with RIA-10% NGS were slightly lower than
those of normal sera, indicating that the physico-chemical
properties of immunoglobulin present in RA sera differ from
those of normal controls, and were modestly retarded by the
detergents contained in RIA-buffer, such as Triton X, sodium
deoxycholate and SDS. Comparable results were observed in
the Costar covalent plate (data not shown).
Furthermore, to determine BG noise values in actual
assays for IgG and IgA antibodies in human sera, the wells
were blocked with ChonBlock™ at room temperature for
1 h, and reacted with the RA sera diluted at 1/100 and 1/
1000 with ChonBlock™. As shown in Fig. 2b, BG noise values
caused by IgG and IgA in serum specimens were almost
completely eliminated when the samples were diluted at 1/0.0
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Fig. 1. Hydrophobic binding of human serum immunoglobulin to plastic surfaces: Co
patient with RA (RA #3) was serially diluted with individual buffers, and added to
covalent plates (b). Immunoglobulin bound to the wells was determined by using100 for IgG, and 1/1000 for IgA antibody assay, although
apparent non-specific reactions caused by serum IgA
remained at a 1/100 dilution.
3.2. Other false positive and negative reactions encountered
with commonly used buffer systems
In addition to the intense false positive reaction caused by
the sample itself (BG noise reaction), four other types of
non-specific reactions are generally seen in an ELISA. To reveal
these false positive and negative reactions in individual buffer
systems, two types of antigens, CCP and E. coli, were selected as
examples, because CCP is widely used as an autologous antigen
for diagnostic purposes for RA, whereas E. coli, which is a
particle antigenwith a complex surface structure, is considered
to be a typical antigen that strongly interacts with serum
immunoglobulin in a non-specific manner. In addition, E. coli
present in the gastrointestinal tract of animals and humans is
consistently interacting with the host's immune system, thus
the antibody response to E. colimight be a valuable marker for
the immune function of individuals.
3.2.1. False positive and negative reactions in anti-CCP antibody
assay in various buffer systems
Anti-CCP-antibody positive serum from a patient with RA
(#353) was serially diluted with RIA-10% NGS, 100% NGS and
ChonBlock™ respectively, and reacted with non-antigen-
coupled, control peptide (cf0-cyc)- and CCP (cf1-cyc)-coupled
wells of Costar covalent plates. According to the method
described by Schellekens et al. (Schellekens et al., 2000) and
Perez et al. (Pérez et al., 2006), the plates were blocked with
IgG-free BSA in the assay using RIA-10% NGS, whereas the
other plates were blocked with the corresponding buffers just
before use.
In the RIA-10% NGS system, virtually identical dilution
curves were observed in antigen non-coupled plain wells100 1000
Serum Dilution 
b) Costar Covalent Plate
: TSB & RIA
: 1% BSA-Tween
: Casein-Tween 
: RIA-10% NGS 
: NGS 
: ChonBLock
mparison of blocking effects of various sample dilution buffers. Serum from a
antigen non-coated plain wells of high affinity Immulon 2 HD (a) and Costar
HRP conjugated goat anti-human IgG antibody.
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Fig. 2. Comparison of IgG BG noise values of normal and RA sera in different buffer systems (a) and IgG and IgA background noise values of RA sera in the
ChonBlock™ buffer system (b). (a) Sera obtained from 10 normal controls (NL) and 10 patients with RA in plain centrifuge tubes were diluted at 1/200 with
individual buffers, and added to antigen non-coated plain wells of an Immulon 2 plate, which was not blocked. (b) Sera from 6 patients with RA diluted at 1/100
and 1/1000 with ChonBlock™ were added to plain wells blocked with ChonBlock™, and the IgG and IgA bound to wells were determined with HRP-conjugated
goat anti-IgG and IgA antibodies, respectively.
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(Fig. 3a–i). Interestingly, OD values in wells lacking antigen,
but blocked with BSA (closed square), were higher than the
OD values seen in CCP peptide (open circle) and control
peptide-coupled wells (closed triangle), indicating that BSA
bound to wells was strongly recognized by antibodies
present in human serum. Importantly, this result also
indicates that BSA bound by SDS in the RIA buffer is not
capable of neutralizing the anti-BSA antibodies present in
human serum.
Importantly, in the RIA-10%NGS buffer system, theODvalues
in CCP-coupled wells (Fig. 3a–i) were lower than the corre-
sponding OD values in the ChonBlock™ system (Fig. 3a–iii),
indicating that NGS-supplemented to RIA buffer partially
inhibited the binding of human serum anti-CCP antibodies to
CCP. Indeed, this inhibitory effect of NGSwas evenmore evident
when100%NGSwas used (Fig. 3a–ii). In contrast, a good dilution
curvewith a lowbackground (Fig. 3a–iii)was achieved using the
ChonBlock™ system. Furthermore, no reaction was seen when
the structurally similar but antigenically unique control peptide
was used in the assay using ChonBlock™ (Fig. 3a–iii, closed
triangle), confirming the high specificity of anti-CCP antibodies
to CCP.3.2.2. False positive and negative reactions in anti-E. coli
antibody assay in various buffer systems
Similarly, significantly divergent dilution curves were ob-
served in anti-E. coli antibody assays in the different buffer
systems used (Fig. 3b). The OD values in E. coli coated wells
(open circle) in the 1%BSA-Tween system (Fig. 3b–i) were
significantly higher than those seen in other buffer systems
(Fig. 3b–ii and iii). As expected, 100% NGS significantly inhibited
the detection of anti-E. coli antibodies (Fig. 3b–i), whereasChonBlock™ provided a clear dilution curve (Fig. 3b–iii) with
low background.3.3. Inhibition studies for conﬁrming assay speciﬁcity and
accuracy of anti-CCP and anti-E. coli antibody assays
To resolve these apparent discrepancies between the
assay data obtained by different buffer systems, inhibition
tests were performed with the corresponding buffers
(Fig. 4). Using the RIA-10% NGS buffer system, an apparent
inhibition (approximately 80%) by CCP was observed (data
not shown). However, the BG noise values in antigen
non-coated control wells were higher than the OD values
in antigen-coated wells, rendering the data uninterpretable.
Therefore, Triton X buffer, which is provided in a commercial
anti-CCP antibody assay kit, was used in subsequent
inhibition studies. Interestingly, the Triton X buffer signifi-
cantly reduced the BG noise value (Fig. 4a, closed triangle),
however only a 53% of inhibition by CCP was achieved
(Fig. 4a, open triangle). In contrast, nearly complete
inhibition (92%) was achieved with the ChonBlock™ buffer
system without any non-specific BG noise reaction (Fig. 4a,
open circle). As anticipated, the control peptide (Fig. 4a,
open square) had no inhibitory effect, indicating that the
human anti-CCP antibodies can be assayed without inter-
ference by immunoglobulins in test serum with the
ChonBlock™ buffer system.
Likewise, nearly complete inhibition (96%) of anti-E. coli
antibodies was achieved with ChonBlock™ (Fig. 4b, open
circle), whereas only 73% inhibition was obtained with 1%
BSA-Tween (Fig. 4b, open triangle), indicating that BSA was
incapable of preventing the non-specific interaction between
immunoglobulins in test samples and E. coli particles.
0.0
0.5
1.0
1.5
2.0
2.5
i) RIA-10% NGS
Non-coated
CCP
Control-Peptide
0.0
0.5
1.0
1.5
2.0
2.5
Serum Dilution
ii) 100% NGS
Non-coated
CCP
0.0
0.5
1.0
1.5
2.0
2.5
iii) ChonBlockTM
Non-coated
CCP
Control-Peptide
O
D4
50
0.0
0.5
1.0
1.5
2.0
2.5
3.0
i) 1% BSA-Tween
Non-coated
E. coli
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Serum Dilution
ii) 100% NGS
Non-coated
E. coli
0.0
0.5
1.0
1.5
2.0
2.5
3.0
iii) ChonBlockTM
Non-coated
E. coli
O
D4
50
a)
b)
Fig. 3. Comparison of anti-CCP (a) and anti-E. coli (b) antibody assay results in different buffer systems. (a) Serum from a patient with RA (RA # 353) positive for
anti-CCP IgG antibody was serially diluted with RIA-10% NGS, 100% NGS and ChonBlock™, and added to antigen non-coupled, control peptide- and CCP-coupled
wells of Costar plates at room temperature for 2 h. All wells were blocked with 2% BSA, 100% NGS, and ChonBlock™, respectively, before adding samples.
(b) Serum from a normal control (NL # 2) was serially diluted with 1% BSA-Tween, 100% NGS and ChonBlock™, and reacted with antigen non-coated and
E. coli-coated Immulon 2 plates at room temperature for 2 h. All wells were blocked with individual buffers before adding samples. IgG antibodies bound to CCP
and E. coli were determined with an HRP-conjugated goat anti-IgG antibody.
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Based on these observations, it was apparent that
ChonBlock™ provides substantial promise as a highly effective
sample dilution buffer for assaying human serum antibodies
against a variety of antigens at low and high serumdilutions. To
confirm the beneficial effects of ChonBlock™, CCP was chosen
as an example of an autologous antigen, and 13 normal and 13
RA sera were assayed at 1/500 dilution using the RIA-10% NGS
and the ChonBlock™ buffer systems. In this assay, glycine-
coupled wells rather than BSA-blocked wells were used to
determine the BG noise values of individual samples.
As shown in Fig. 5a, in the RIA buffer system, similar OD
values were observed in all three wells (glycine-, control
peptide- and CCP-coupled) for both normal and RA sera,
except 2 RA sera. Importantly, if the OD values obtained inCCP-coupled wells are corrected by subtracting the BG OD
values obtained in glycine-coupled control wells, the corrected
OD values are as low as 0.040 ± 0.066 for normal sera, and
0.377 ± 0.652 for RA sera. As a consequence, no significant
difference was observed between normal and RA in the
RIA-10% NGS buffer system (Fig. 5a) due to high BG noise
reactions and inhibition of anti-CCP antibodies by NGS.
In contrast, when the samples were diluted with
ChonBlock™, OD values of normal sera in two control wells
and CCP-coupled wells were equally low (Fig. 5b). Similarly, OD
values of RA sera in two control wells were low, but apparently
high in CCP-coupled wells. Interestingly, when the OD values in
CCP-coupled wells are corrected by subtracting the OD values in
Gly-coupled wells, the average ± SD value of normal and RA
sera was 0.050 ± 0.041 and 1.253 ± 1.322 (p = 0.003), re-
spectively. Importantly, the corrected OD values in 2/13 normal
0.0
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O
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Fig. 4. Inhibition tests of anti-CCP (a) and anti-E. coli (b) antibodies in different buffer systems. (a) Serum (RA #3) diluted at 1/800 with RIA-10% NGS, Triton X or
ChonBlock™ buffer was mixed with a control-peptide and CCP-peptide solution (0.1–1 mg/ml), respectively as described in the Materials & methods section. After
incubation at 4 °C overnight, sample solutions were added to antigen non-coupled and CCP-coupled wells at room temperature for 2 h. b) An E. coli suspension in distilled
water (OD600 value: 10) was aliquoted into micro-centrifuge tubes and mixed with human serum (NL #2) diluted at 1/100 with 1% BSA-Tween or ChonBlock™, and
incubated at 4 °C overnight as described in the Materials & methods section. The supernatant was then diluted to 1/2500 with individual buffers, and added to antigen
non-coated and E. coli-coated Immulon 2 plates at room temperature for 2 h. IgG antibodies bound to CCP and E. coli were determined with an HRP-conjugated goat
anti-IgG antibody.
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and considered positive for anti-CCP antibodies (see CCP-Gly
of normal in Fig. 5b). These results clearly indicate the
importance of determining BG noise values of individual
samples, and to correct the OD values in antigen-coated
wells by subtracting the OD values in control wells
regardless of the antigen and buffer system used, especially
at low serum dilutions.a) RIA-10% NGS
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Glycine was used as control antigen instead of BSA to determine the BG noise valu
corrected by subtracting the BG noise OD values in glycine-coupled wells (CCP-Gly3.5. Measuring IgG and IgA antibody responses against potential
pathogenic agents in autoimmune diseases by ELISA using the
ChonBlock™ buffer system
To study a possible involvement of environmental agents
in the pathogenesis of autoimmune diseases, IgG and IgA
antibody levels to potential pathogenic environmental agents
(E. coli, LPS, PG-PS and Pg-LPS) and IgG antibody responses tob) ChonBlockTM
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Fig. 6. IgG and IgA antibody levels to potential pathogenic environmental agents in normal controls and patients with RA, SLE, and Crohn's disease. Serum samples
were diluted with ChonBlockTM at 1/1000 to 1/20,000 depending on antigens, and assayed for IgG and IgA antibodies, respectively, as described in the Materials &
methods section, *: p N 0.05, **: p N 0.01 (compared to normal controls).
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were measured in sera from 16 normal controls, 61 patients
with RA, 7 patients with SLE, and 7 patients with Crohn's
disease by ELISA using the ChonBlock™ buffer system. Since
RA is believed to be polyvalent diseases rather than a single
disease influenced by genetic backgrounds, RA patients were
divided into 4 groups depending on HLA-haplotypes, G1: 15patients with homozygous DR4 (O401/0405, 0404, 0408),
G2: 16 patients with heterozygous DR1 (01/03, 0707, 0901,
11, 13, 15/16), G3: 16 patients with miscellaneous HLA types,
and G4: 14 patients with heterozygous DR4 (0401/01, 03,
0403, 11/12, 15/16).
As shown in Fig. 6a, IgG antibody responses to E. coliwere
significantly lower in all 4 RA groups and SLE compared to
23K. Terato et al. / Journal of Immunological Methods 407 (2014) 15–25those of normal controls. Similarly, IgG antibody responses to
LPS and PG-PS tended to be lower in RA. In contrast, IgG
antibody responses to these antigens including Pg-LPS were
significantly higher in Crohn's disease. A similar trend was
observed in IgG antibody responses to dietary proteins (OVA,
BSA, and bovine IgG), but no significant difference was
observed due to wide deviations in antibody levels among
individuals rather than groups (data not shown). In contrast,
IgA antibody responses to these antigens were equal or
tended to be higher in RA and SLE compared to normal
controls (Fig. 6b). Accordingly, SLE shares a similar IgG and
IgA antibody response pattern to those of RA, but was
differentiated by higher IgA responses to LPS (Fig. 6b). On the
other hand, Crohn's disease was distinguished from RA and
SLE based on significantly high IgG antibody responses to
E. coli, LPS and Pg-LPS as shown in Fig. 6a.
As a consequence of lower IgG and higher IgA antibody
responses, the IgA/IgG anti-E. coli antibody ratios were
significantly higher in G1 (p N 0.01), G2 (p N 0.01) and G3
(p N 0.01) of RA and SLE (p N 0.05) as well as the IgA/IgG
anti-LPS antibody ratios in G1 (p N 0.05) and G2 (p N 0.05) of
RA and SLE (p N 0.01) as shown in Fig. 6c. Contrary, no
significant high IgA/IgG ratio was observed in Crohn's
disease, in which IgG antibody responses to all three antigens
were concurrently higher than those of normal controls, RA
and SLE, except for the IgG antibody respose to PG-PS.
4. Discussion
False positive antibody studies encountered in the assay of
antibodies in human sera are a too common of an occurrence
and are not restricted to any one particular type of antigen. If
proper precautions are not taken in the development of an
assay and interpreting its results, the outcome can be most
unfortunate. The literature is replete with such examples. This
problem appears more common in the study of human sera
where lower dilutions are used to enhance assay sensitivity.
Nevertheless, strong false positive reactions can still be seen
even with sera dilutions of 1/2000 or greater. Without being
aware of the intense false positive reaction caused by the
sample itself and other non-specific reactions, antibodies
against a variety of antigens were assayed in human sera at
low dilution as low as 1/20-1/200, as described later.
In this study, we re-confirmed that none of the conven-
tional ELISA buffers are capable of blocking the significantly
high BG noise reaction caused by hydrophobic binding of
immunoglobulin components in human sera to plastic surfaces
(Figs. 1 and 2).Moreover, conventional bufferswere ineffective
compared to ChonBlock™ at reducing false positive (Fig. 3a–i &
b–i) and negative reactions (Fig. 3a–ii and b–ii) in anti-CCP and
anti-E. coli antibody assays. In addition, the new buffer
effectively eliminates the false positive reaction caused by a
common blocking agent, bovine serum albumin (BSA), as well
as negative reactions due to denaturing detergents such as SDS,
and inhibiting antibodies in heterologous serum supplemented
to sample dilution buffers as shown in Fig. 3a–iii and b–iii.
Indeed, the data show that the new buffer is applicable for
assaying antibodies against awide variety of antigens including
environmental agents and dietary proteins such as E. coli, LPS,
Pg-LPS, BSA and OVA and autologous components such as CCP
and collagen.Using the new buffer system for this preliminary study,
the data show that IgG antibody responses to E. coli and LPS
are significantly lower or tend to be lower in patients with RA
and SLE compared to normal controls (Fig. 6a, b & c), and as a
consequence, the IgA/IgG antibody ratios are significantly
higher in these patients (Fig. 6c). It cannot be ruled out that
there is a possibility that steroids prescribed for these patients
suppressed the IgG antibody responses; however, it is unlikely
that steroids specifically affected the IgG antibody response
without affecting the IgA antibody response. One possible
explanation for the higher IgA/IgG antibody ratios in RA and
SLE is that these patientsmight be chronically exposed to excess
amounts of these potential environmental pathogenic agents.
This may be a consequence of an imbalance of enteromicrobes
in the gastrointestinal tract. In contrast, Crohn's disease was
characterized by high IgG antibody responses not only to E coli
and LPS, but also to Pg-LPS (Fig. 6a), suggesting that their
immune systems are systemically and excessively stimulated by
these antigens, which have penetrated into the body due to
leakage of the mucosal barrier. Although it has been suggested
that Crohn's disease may be linked to periodontal disease,
because of the high IgG antibody responses to P. gingivalis
(Habashneh et al., 2012), our data show that Crohn's disease
patients have high antibody titers against all the antigens tested
(Fig. 6a) including Pg-LPS, suggesting that excess amounts of
Pg-LPS aswell as other antigens are simply translocated through
the intestinal mucosal membrane due to poor gut barrier
function in these patients. Similarly, an association of periodon-
titis and RA has also been considered (Mikuls et al., 2009),
although it still remains uncertain whether there is an
etiological link or simply represents statistical coincidence
(Farquharson et al., 2012). However, our data suggest that
periodontitis may not be linked to RA, since no difference in IgG
and IgA antibody responses to Pg-LPS between normal and RA
was observed (Fig. 6a & b). These significant differences in
immune responses to potential pathogenic agents between
RA and Crohn's disease suggest pathogenic mechanisms and
potential pathogens involved in RA and Crohn's disease may
differ.
Notably, our observations in this study are not in
agreement with past studies, which commonly concluded
that antibody levels were higher in disease groups compared
to normal controls; for example, antibodies against E. coli,
Klebsiella pneumoniae nitrogenase, Proteus mirabilis, and
Serratia marcescens (Aoki et al., 1996; Rashid et al., 2004;
Zapata-Quintanilla et al., 2006; Hitchon et al., 2010), LPS
(Maes et al., 2011; Arabski et al., 2012), P. gingivalis (Mikuls
et al., 2009), glucose-6-phosphate isomerase (GPI) (Schaller
et al., 2005), collagen (Collier et al., 1984; Burkhardt et al.,
2006; Nandakumar et al., 2008), human HLA DR and B27
molecules (Takeuchi et al., 1990; Wilson et al., 1995;
Ringrose, 1999), and citrulline (Schellekens et al., 1998;
Pérez et al., 2006), E. coli (Newkirk et al., 2005), heat shock
proteins (Komiya et al., 2011) and advanced glycation end
products (AGEs) (Ligier et al., 1998). In these studies, several
factors apparently contributed to the ELISA results: 1) the
low dilution of test sera, 2) the buffer systems, which are not
capable of blocking the most intense false positive BG noise
reaction caused by the sample itself, and 3) the omission of
antigen non-coated control wells in themapping of ELISA plates
to determine the unique BG noise values of individual samples.
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potential pathogenic antigens with great foresight; however,
the differences in our ELISA results are apparently attributed to
the ability of ChonBlock™ to eliminate the aforementioned
confounding factors in ELISA.
Notwithstanding, the data in this study indicate that lowered
immune responses to potential pathogenic environmental
agents may be the fundamental disorder in autoimmune
diseases. In fact, this idea is supported by numerous studies in
experimental animal models. For example, HLA-B7 transgenic
mice (Reháková et al., 2000) and rats (Taurog et al., 1994) do
not develop ankylosing spondylitis under germ free conditions.
Similarly, GPI specific T-cell transgenic K/BxN mice do not
develop arthritis under germ free conditions (Ivanov et al.,
2009). Importantly, these transgenic rodents develop severe
arthritis when they are transferred to non-SPF conditions or
inoculated with commensal bacteria, indicating that even
commensal bacterium and their toxins can be pathogenic in
these animals, whose immune function is not fully functional,
because of the absence of commensal bacteria, which promote
the development of a mature immune system.
Actually, it has long been considered that environmental
factors such as commensal bacteria and their toxins may
contribute to the pathogenesis of autoimmune disease. For
example, the imbalance of intestinal bacteria may be one
possible etiopathogenic or aggravating factor in RA (Peltonen et
al., 1994, 1997; Kjeldsen-Kragh, 1999; Tlaskalová-Hogenová et
al., 2004; Edwards, 2008; Vaahtovuo et al., 2008) and inflam-
matory bowel disease (IBD) (Lucke et al., 2006; Frank et al.,
2007; Nell et al., 2010). In addition to bacteria, the pathogenic
effects of bacteria toxins produced by enteromicrobes, such as
LPS, have been clearly demonstrated in a variety of animal
models such as collagen-induced arthritis (Yoshino et al., 1999)
and collagen antibody-induced arthritis (Terato et al., 1995),
diabetes (Cani et al., 2007; Nymark et al., 2009), experimental
autoimmune encephalomyelitis (EAE) (Nogai et al., 2005),
SLE-nephritis (Hang et al., 1983; Cavallo and Granholm, 1991),
autoimmune hemolytic anemia (Murakami et al., 1994, 1997),
and in patients with obesity (Cani et al., 2007), type I diabetes
(Nymark et al., 2009) and myalgic encephalomyelitis/chronic
fatigue syndrome (ME/CFS) (Maes et al., 2011).
Recently, Iwatsuki et al. (Iwatsuki et al., 2011) analyzed
intestinal bacteria flora in elderly volunteers treated by oral
administration of a natural milk antibody product, which
contains biologically active antibodies against a wide range of
pathogenic bacteria and their toxins (Kijima et al., 2009), and
found significant reduction in the fecal population of patho-
genic enteromicrobes such as E. coli, Clostridium difficile and
perfringens. This approach was further applied for the treat-
ment of patients with RA, resulting in modulated disease
activities in 50% of these RA patients (Katayama et al., 2011).
Together, these data support the idea that commensals and
their toxinsmay contribute to the pathogenesis of autoimmune
diseases.
To further study the influence of environmental factors on
the immune system, and the potential link to autoimmune
diseases, it is important to determine the differences in
immune function of healthy normal individuals and patients
with autoimmune diseases by assaying antibody responses to
environmental agents. Finally, we hope our ELISA system not
only reforms antibody studies in these fields, but alsoimproves the accuracy of diagnostics in the medical field by
eliminating false positive and negative results.
5. Conclusions
A newly developed ELISA buffer, ChonBlock™, effectively
prevents all types of non-specific reactions involved in ELISA, and
can be applied to studying antibodies against virtually all types of
antigens. Using this new buffer system, we concluded that low
IgG antibody responses to potential pathogenic environmental
factors might be the fundamental disorder in autoimmune
diseases. We assume that patients with autoimmune diseases
might be chronically exposed to excess amounts of potential
pathogenic agents at the gastrointestinal tract due to an
imbalance of enteromicrobes, which may be linked to the host's
low immune function. We hope this report leads future studies
on autoimmune diseases to new directions.
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